A Pharmacokinetic/pharmacodynamic study to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Phase of Trial: Phase IV
Latest Information Update: 16 Feb 2016
At a glance
- Drugs Ceftaroline fosamil (Primary)
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Therapeutic Use
- 16 Feb 2016 According to Allergan media release, the U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil).
- 04 Feb 2016 New trial record